Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Omega Therapeutics, Inc. | Chief Financial Officer | Option (Right to Buy) | 60K | Mar 9, 2022 | Direct | ||
ACTUATE THERAPEUTICS, INC. | Director | Non-Qualified Stock Options | 30K | Aug 12, 2024 | Direct | ||
ALIMERA SCIENCES INC | Director | Stock Option (Right to Buy) | 2.25K | Feb 25, 2023 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
ACTU | ACTUATE THERAPEUTICS, INC. | Aug 12, 2024 | 1 | $0 | 4 | Aug 14, 2024 | Director |
ACTU | ACTUATE THERAPEUTICS, INC. | Aug 12, 2024 | 0 | $0 | 3 | Aug 14, 2024 | Director |
ALIM | ALIMERA SCIENCES INC | Feb 25, 2023 | 1 | $0 | 4 | Mar 1, 2023 | Director |
ALIM | ALIMERA SCIENCES INC | Feb 25, 2023 | 0 | $0 | 3 | Mar 1, 2023 | Director |
OMGA | Omega Therapeutics, Inc. | Mar 9, 2022 | 1 | $0 | 4 | Mar 11, 2022 | Chief Financial Officer |
OMGA | Omega Therapeutics, Inc. | Aug 3, 2021 | 1 | $50K | 4 | Aug 3, 2021 | Chief Financial Officer |
OMGA | Omega Therapeutics, Inc. | Jul 29, 2021 | 0 | $0 | 3 | Jul 29, 2021 | Chief Financial Officer |